Moreover, glioblastoma patients often exhibitblood–brain barrier (BBB) disruption, which, along with increasedvascularization within the tumor region, might favor a higher releaseof tumor-derived EVs from the TME directly to the blood (what doesnot happen with the intact BBB in controls), resulting in higher proportionsof TNC+/CD9+ EVs in their plasma compared toCSF. This evidence concerns the gene CD9 and glioblastoma.